Tuberc Respir Dis.  1972 Jun;19(2):35-38. 10.4046/trd.1972.19.2.35.

The Clinical Effect of Rifampicin for Retreatment Cases for Pulmonary Tuberculosis

• KMID: 2529076
• DOI: http://doi.org/10.4046/trd.1972.19.2.35

Abstract

The authors analyzed the clinical benefits and toxic effects of Rifampicin in 32 patients with prolonged previous chemotherapy wíthout effect (5cases were post-operative). The Rifampicin was given with one or more other anti-Tb. drugs for 3 to 12 months. The doses were 450-600mg once daily or biweekly. Sputum conversion: 14 patients had positive sputum on the begining and 7 patients (50%) became nagative with Rifampicin treatment. X-ray improvement: There was no remarkable change noticed except slight improvement in 7 cases. Symptomatic improvement: Majority of cases showed a decrease of cough and sputm sense of wellbeing, soon after the administration of Rifampicin and also showed some gain of bodyweight. Side effects: There was no serious side effect and serious liver function disturbance detected but one case had chill, fever and general bodyache and another case complained of general bodyache 6 to 7 months after the Rifampicin treatment.